QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Phase 1
Terminated
- Conditions
- Lung CancerPancreatic CancerThyroid CancerOvarian CancerBreast CancerColon Cancer
- Interventions
- Biological: ETBX-011Biological: ALT-803
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- NantCell, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03127098
- Locations
- 🇺🇸
Medical Oncology Associates, Spokane, Washington, United States
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
Phase 2
Completed
- Conditions
- Chordoma
- Interventions
- Biological: GI-6301 Vaccine (Yeast- Brachyury)Other: PlaceboRadiation: RadiotherapyDevice: wGT3X-BT Actigraph
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- NantCell, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02383498
- Locations
- 🇺🇸
NIH Clinical Center, Bethesda, Maryland, United States
QUILT-3.006 for Recurrent Medullary Thyroid Cancer
Phase 2
Completed
- Conditions
- Medullary Thyroid Cancer (MTC)
- Interventions
- Biological: GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- NantCell, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT01856920
- Locations
- 🇺🇸
NIH Clinical Center, Bethesda, Maryland, United States
QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
Phase 3
Completed
- Conditions
- Adenocarcinoma of the PancreasAdvanced Solid TumorsCancerCancer of PancreasMetastatic Pancreatic CancerPancreas CancerCancer of the PancreasMetastasesMetastatic CancerPancreatic Cancer
- Interventions
- First Posted Date
- 2010-11-01
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- NantCell, Inc.
- Target Recruit Count
- 800
- Registration Number
- NCT01231347
- Locations
- 🇬🇧
Research Site, Northampton, United Kingdom
QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid TumorsCancerSolid TumorsTumorsAdvanced Malignancy
- Interventions
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- NantCell, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00974896
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
Phase 1
Terminated
- Conditions
- Colorectal CancerLocally AdvancedSarcomaSolid TumorsNon-Small Cell Lung CancerOvarian CancerPancreatic CancerMetastatic Cancer
- Interventions
- Biological: AMG 479Biological: AMG 655
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- NantCell, Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT00819169
QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
Phase 2
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Other: FOLFIRIOther: PlaceboBiological: AMG 655Biological: AMG 479
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- NantCell, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT00813605
- Locations
- 🇪🇸
Research Site, Madrid, Spain
QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
Phase 1
Terminated
- Conditions
- Advanced Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-12-12
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- NantCell, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT00807612
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer
Phase 1
Terminated
- Conditions
- Extensive-stage Small Cell Lung CancerLung CancerSolid TumorsSmall Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- NantCell, Inc.
- Target Recruit Count
- 213
- Registration Number
- NCT00791154
QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer
Phase 1
Completed
- Conditions
- Metastatic Pancreatic CancerPancreatic CancerAdenocarcinoma of the Pancreas
- Interventions
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- NantCell, Inc.
- Target Recruit Count
- 138
- Registration Number
- NCT00630552
- Locations
- 🇺🇸
Research Site, Yakima, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath